


Reference Data

(Consolidated Financial Results for Q2 FY2015)



Daiichi-Sankyo

October 30, 2015

Daiichi Sankyo Co., Ltd.

<http://www.daiichisankyo.com>

Contents

1.	Consolidated Statement of Profit or Loss	P1
2.	Revenue of Global Products	P2
3.	Revenue by Business Units and Products	P3
4.	Consolidated Statement of Financial Position	P6
5.	Consolidated Statement of Cash Flows	P8
6.	Number of Employees	P9
7.	Capital Expenditure and Depreciation and Amortization	P9
8.	Summary of Product Outlines	P10
9.	Quarterly Data	P11
10.	Historical Data	P16
11.	Major R&D Pipeline (Innovative pharmaceuticals)	P20

1. Consolidated Statement of Profit or Loss

JPY Bn	FY2014 Q2 YTD		FY2015 Q2 YTD					FY2015						
	to revenue	Results	to revenue	Results	(vs. Forecast (%))	YoY	YoY (%)	to revenue	Forecast (as of Jul.)	to revenue	Forecast (as of Oct.)	vs. Forecast (as of Jul.)	YoY	YoY (%)
Revenue	100.0%	429.6	100.0%	478.8	(48.9%)	49.2	+11.4%	100.0%	950.0	100.0%	980.0	30.0	60.6	+6.6%
Cost of sales	30.4%	130.8	31.1%	148.9	(47.4%)	18.1	+13.9%	31.8%	302.0	32.0%	314.0	12.0	-9.1	-2.8%
(excl. Special items)	30.4%	130.8	31.8%	152.4		21.6	+16.5%							
(Special items)	-	-	-0.7%	-3.5		-3.5								
Gross Profit	69.6%	298.8	68.9%	329.8	(49.5%)	31.0	+10.4%	68.2%	648.0	68.0%	666.0	18.0	69.7	+11.7%
SG&A expenses	35.8%	153.7	30.2%	144.5	(40.8%)	-9.2	-6.0%	35.6%	338.0	36.1%	354.0	16.0	22.8	+6.9%
(excl. Special items)	34.8%	149.6	31.9%	152.7		3.0	+2.0%							
(Special items)	0.9%	4.0	-1.7%	-8.2		-12.2	-304.5%							
R&D expenses	19.8%	84.9	18.5%	88.4	(46.0%)	3.5	+4.1%	20.0%	190.0	19.6%	192.0	2.0	1.3	+0.7%
(excl. Special items)	19.8%	84.9	18.5%	88.4		3.5	+4.1%							
(Special items)	-	-	-	-		-								
Operating Profit	14.0%	60.2	20.3%	97.0	(80.8%)	36.8	+61.0%	12.6%	120.0	12.2%	120.0	0.0	45.6	+61.2%
(Operating Profit before Special items)	15.0%	64.3	17.8%	85.3		21.1	+32.8%							
Financial income/expenses		2.8		-5.9		-8.6								
Share of profit or loss of investments accounted for using the equity method		-0.8		-0.3		0.5								
Profit before tax	14.5%	62.2	19.0%	90.8	(79.0%)	28.6	+46.1%	12.1%	115.0	11.7%	115.0	0.0	35.1	+43.9%
Income taxes		26.9		21.4		-5.6	-20.6%							
Profit for the year	8.2%	35.2	14.5%	69.4		34.2	+97.1%							
Profit attributable to owners of the Company	8.5%	36.7	14.8%	70.7	(94.3%)	34.0	+92.8%	7.9%	75.0	7.7%	75.0	0.0	28.5	+61.4%
Tax rate		43.3%		23.5%										
Overseas sales ratio		43.1%		46.5%										
Currency Rate (Average)								Currency Rate (Average)						
USD/JPY		103.05		121.80					120.34		120.90			
EUR/JPY		138.91		135.07					131.04		132.53			

Forex impact: +23.8
(USD: +22.2, EUR: -1.1, ASCA: +2.7)

Forex impact: +6.0
(USD: +5.1, ASCA: +1.0)

FY2015: Gain on sales of subsidiary -2.4, Gain on sales of fixed assets -1.1

Forex impact: +8.9
(USD: +8.6, EUR: -0.6, ASCA: +0.9)

FY2014: Settlement expenses with US Department of Justice +4.0
FY2015: Gain on sales of fixed assets -8.2

Forex impact: +4.5
(USD: +4.6, EUR: -0.1)

Forex impact: +4.4
(USD: +4.0, EUR: -0.4, ASCA: +0.8)

FY2015: Expenses relating to sale of Sun Pharma shares etc.

Increase in R&D tax credit

Annual impact of one yen change

	Forecast (as of Jul.)		Forecast (as of Oct.)	
	USD	EUR	USD	EUR
Revenue	2.1 Bn Yen	0.6 Bn Yen	2.2 Bn Yen	0.6 Bn Yen
Operating Profit	minor	minor	0.2 Bn Yen	0.1 Bn Yen

*At the time of disclosure of this report, the audit procedures for financial statements are in progress in accordance with the Financial Instruments and Exchange Act.

*The figures for FY2014 have been restated and indicated as only the values for continuing operations excluding Ranbaxy.

*Special items : Items having a transitory and material impact on operating profit are defined as "Special items".
Specifically, gains and losses related to: sale of fixed assets, restructuring, impairment, litigation, etc. amounting to 1 billion JPY or more are defined as "Special items".

2. Revenue of Global Products

JPY Bn		FY2014 Q2 YTD	FY2015 Q2 YTD				FY2015		
		Results	Results	(vs. Forecast (%))	YoY	YoY (%)	Forecast (as of Jul.)	Forecast (as of Oct.)	vs. Forecast (as of Jul.)
	Olmesartan antihypertensive	142.2	147.5	(52.0%)	5.3	+3.7%	283.0	284.0	1.0
	Olmetec (JPN)	37.8	36.2	(45.8%)	-1.6	-4.3%	79.0	79.0	0.0
	Rezaltas (JPN)	9.0	8.9	(46.9%)	-0.1	-1.0%	19.0	19.0	0.0
	Benicar/Benicar HCT (US)	34.0	40.3	(55.3%)	6.4	+18.8%	73.0	73.0	0.0
	Azor (US)	8.0	10.4	(61.5%)	2.4	+30.1%	17.0	17.0	0.0
	Tribenzor (US)	5.2	6.3	(63.4%)	1.1	+22.1%	10.0	10.0	0.0
	Olmetec/Olmetec Plus (EU)	20.4	17.1	(53.3%)	-3.3	-16.3%	32.0	32.0	0.0
	Sevikar (EU)	9.6	8.5	(53.3%)	-1.0	-10.9%	15.0	16.0	1.0
	Sevikar HCT (EU)	5.4	4.6	(51.6%)	-0.8	-14.7%	9.0	9.0	0.0
	Other subsidiaries, export, etc	12.9	15.0	(51.9%)	2.2	+16.9%	29.0	29.0	0.0
	Prasugrel antiplatelet	11.7	15.3	-	3.6	+30.7%	not disclosed	not disclosed	-
	Effient alliance revenue (US)	8.5	10.6	-	2.1	+25.1%	not disclosed	not disclosed	-
	Efient alliance revenue and others (EU)	2.3	2.2	-	-0.1	-5.2%	not disclosed	not disclosed	-
	Efient (JPN)	0.3	1.8	(35.3%)	1.5	+461.0%	5.0	5.0	0.0
	Other subsidiaries, export, etc	0.6	0.7	-	0.1	+22.2%	not disclosed	not disclosed	-
	Edoxaban anticoagulant	0.2	5.3	(36.4%)	5.2	+2602.9%	14.7	14.7	0.0
	Lixiana (JPN)	0.2	5.4	(48.8%)	5.2	+2612.0%	11.0	11.0	0.0
	Savaysa (US)	-	-0.2	-	-0.2	-	2.0	2.0	0.0
	Lixiana (EU)	-	0.2	(9.4%)	0.2	-	1.7	1.7	0.0

3. Revenue by Business Units and Products (1)

JPY Bn	FY2014 Q2 YTD		FY2015 Q2 YTD				FY2015		
	Results		Results	(vs. Forecast (%))	YoY	YoY (%)	Forecast (as of Jul.)	Forecast (as of Oct.)	vs. Forecast (as of Jul.)
Japan	222.6		227.8	(46.4%)	5.2	+2.3%	488.0	491.0	3.0
Olmetec	37.8		36.2	(45.8%)	-1.6	-4.3%	79.0	79.0	0.0
Nexium	32.1		38.7	(50.2%)	6.6	+20.6%	74.0	77.0	3.0
Memary	16.8		20.5	(43.6%)	3.7	+22.2%	47.0	47.0	0.0
Loxonin	25.4		24.4	(55.4%)	-1.0	-3.9%	44.0	44.0	0.0
Cravit	14.2		9.0	(52.9%)	-5.2	-36.5%	17.0	17.0	0.0
Rezaltas	9.0		8.9	(46.9%)	-0.1	-1.0%	19.0	19.0	0.0
Artist	9.4		7.9	(46.4%)	-1.5	-16.3%	17.0	17.0	0.0
Omnipaque	8.6		8.5	(52.8%)	-0.1	-1.7%	16.0	16.0	0.0
Mevalotin	8.3		7.0	(49.7%)	-1.3	-16.1%	14.0	14.0	0.0
Ranmark	4.7		5.9	(45.2%)	1.2	+25.8%	13.0	13.0	0.0
Inavir	0.3		0.0	(0.3%)	-0.3	-86.3%	12.0	12.0	0.0
Urief	5.6		5.7	(51.8%)	0.1	+2.0%	11.0	11.0	0.0
Pralia	3.0		5.4	(53.5%)	2.4	+79.6%	10.0	10.0	0.0
Lixiana	0.2		5.4	(48.8%)	5.2	+2612.0%	11.0	11.0	0.0
Efient	0.3		1.8	(35.3%)	1.5	+461.0%	5.0	5.0	0.0
Teneria	3.3		5.3	-	2.0	+61.8%	not disclosed	not disclosed	-
Daiichi Sankyo Espha products	6.8		8.6	-	1.8	+25.7%	not disclosed	not disclosed	-
Vaccines business	12.5		14.4	-	1.9	+15.1%	not disclosed	not disclosed	-
Daiichi Sankyo Healthcare (OTC)	22.7		24.6	(50.3%)	2.0	+8.7%	48.0	49.0	1.0

3. Revenue by Business Units and Products (2)

JPY Bn	FY2014 Q2 YTD		FY2015 Q2 YTD				FY2015		
	Results		Results	(vs. Forecast (%))	YoY	YoY (%)	Forecast (as of Jul.)	Forecast (as of Oct.)	vs. Forecast (as of Jul.)
Daiichi Sankyo, Inc. (US)	78.1		93.4	(53.0%)	15.2	+19.5%	166.0	176.0	10.0
Olmesartan antihypertensive	47.2		57.1	(56.6%)	9.9	+21.1%	101.0	101.0	0.0
Benicar/Benicar HCT	34.0		40.3	(55.3%)	6.4	+18.8%	73.0	73.0	0.0
Azor	8.0		10.4	(61.5%)	2.4	+30.1%	17.0	17.0	0.0
Tribenzor	5.2		6.3	(63.4%)	1.1	+22.1%	10.0	10.0	0.0
Welchol antihyperlipidemic / type 2 diabetes	21.8		24.2	(51.5%)	2.4	+11.0%	37.0	47.0	10.0
Effient antiplatelet	8.5		10.6	-	2.1	+25.1%	not disclosed	not disclosed	-
Savaysa anticoagulant	-		-0.2	-	-0.2	-	2.0	2.0	0.0
Movantik opioid-induced constipation	-		0.6	-	0.6	-	not disclosed	not disclosed	-
Luitpold Pharmaceuticals, Inc. (US)	26.8		46.4	(54.0%)	19.6	+73.4%	76.0	86.0	10.0
Venofer iron deficiency anemia	14.2		16.0	(53.4%)	1.8	+12.7%	28.0	30.0	2.0
Injectafer iron deficiency anemia	2.9		7.9	(46.4%)	5.0	+169.4%	17.0	17.0	0.0
Daiichi Sankyo Europe GmbH	44.5		39.2	(51.6%)	-5.3	-11.9%	75.0	76.0	1.0
Olmesartan antihypertensive	35.4		30.2	(52.1%)	-5.2	-14.6%	57.0	58.0	1.0
Olmetec/Olmetec Plus	20.4		17.1	(53.3%)	-3.3	-16.3%	32.0	32.0	0.0
Sevikar	9.6		8.5	(53.3%)	-1.0	-10.9%	15.0	16.0	1.0
Sevikar HCT	5.4		4.6	(51.6%)	-0.8	-14.7%	9.0	9.0	0.0
Effient antiplatelet	2.3		2.2	-	-0.1	-5.2%	not disclosed	not disclosed	-
Lixiana anticoagulant	-		0.2	(9.4%)	0.2	-	1.7	1.7	0.0
Asia, South and Central America (ASCA)	30.0		42.7	(48.5%)	12.8	+42.6%	88.0	88.0	0.0
Daiichi Sankyo China	11.5		16.4	-	4.9	+42.6%	not disclosed	not disclosed	-
Daiichi Sankyo Taiwan	2.3		2.7	-	0.4	+16.3%	not disclosed	not disclosed	-
Daiichi Sankyo Korea	4.4		4.8	-	0.4	+8.9%	not disclosed	not disclosed	-
Daiichi Sankyo Thailand	1.6		1.8	-	0.2	+11.6%	not disclosed	not disclosed	-
Daiichi Sankyo Brasil Farmacêutica	4.3		4.5	-	0.3	+6.1%	not disclosed	not disclosed	-
Daiichi Sankyo Venezuela	3.0		5.5	-	2.5	+82.1%	not disclosed	not disclosed	-

3. Revenue by Business Units and Products (3)

[Reference] Revenue in Local Currency

USD Mn

	FY2014 Q2 YTD	FY2015 Q2 YTD				FY2015		
	Results	Results	(vs. Forecast (%))	YoY	YoY (%)	Forecast (as of Jul.)	Forecast (as of Oct.)	vs. Forecast (as of Jul.)
Daiichi Sankyo, Inc. (US)	758	766	(52.4%)	8	+1.1%	1,379	1,462	83
Olmesartan antihypertensive	458	469	(55.7%)	11	+2.4%	842	842	0
Benicar/Benicar HCT	330	331	(54.5%)	2	+0.5%	608	608	0
Azor	78	86	(60.6%)	8	+10.1%	142	142	0
Tribenzor	50	52	(62.5%)	2	+3.3%	83	83	0
Welchol antihyperlipidemic / type 2 diabetes	211	199	(50.9%)	-13	-6.1%	307	390	83
Effient antiplatelet	82	87	-	5	+5.9%	not disclosed	not disclosed	-
Savaysa anticoagulant	-	-1	-	-1	-	17	17	0
Movantik opioid-induced constipation	-	5	-	5	-	not disclosed	not disclosed	-

USD Mn

Luitpold Pharmaceuticals, Inc. (US)	260	381	(53.3%)	121	+46.7%	632	714	83
Venofer iron deficiency anemia	138	132	(52.8%)	-6	-4.7%	233	249	17
Injectafer iron deficiency anemia	28	65	(45.8%)	36	+127.9%	141	141	0

EUR Mn

Daiichi Sankyo Europe GmbH	321	290	(49.7%)	-30	-9.4%	577	584	8
Olmesartan antihypertensive	255	224	(50.2%)	-31	-12.2%	438	446	8
Olmetec/Olmetec Plus	147	126	(51.3%)	-20	-13.9%	246	246	0
Sevikar	69	63	(51.3%)	-6	-8.3%	115	123	8
Sevikar HCT	39	34	(49.7%)	-5	-12.2%	69	69	0
Effient antiplatelet	17	16	-	-0	-2.5%	not disclosed	not disclosed	-
Lixiana anticoagulant	-	1	(9.1%)	1	-	13	13	0

4. Consolidated Statement of Financial Position

<Assets>

(JPY Bn)

	Mar. 2015	Sep. 2015	vs. Mar. 2015
Assets			
Current assets			
Cash and cash equivalents	189.4	235.4	46.0
Trade and other receivables	241.5	250.5	9.0
Other financial assets	186.5	470.0	283.6
Inventories	150.1	153.3	3.2
Other current assets	14.7	14.8	0.1
Subtotal	782.2	1,123.9	341.8
Assets held for sale	3.2	-	-3.2
Total current assets	785.3	1,123.9	338.6
Non-current assets			
Property, plant and equipment	266.5	265.4	-1.1
Goodwill	71.4	71.2	-0.2
Intangible assets	199.4	212.1	12.7
Investments accounted for using the equity method	1.3	1.0	-0.3
Other financial assets	593.9	162.9	-431.0
Deferred tax assets	45.3	45.4	0.0
Other non-current assets	19.1	18.9	-0.2
Total non-current assets	1,197.0	776.9	-420.0
Total assets	1,982.3	1,900.9	-81.4
* Liquidity on hand	374.3	703.9	329.5
Debt with interest	224.6	224.2	-0.4
Net Cash	149.7	479.7	329.9

Increase due to sale of Sun Pharma shares

Acquired +20.9, Amorization -8.1

Sale of Sun Pharma shares -424.3
(Sale: -378.5, Evaluation difference -45.8)

<Liabilities and equity>

(JPY Bn)

	Mar. 2015	Sep. 2015	vs. Mar. 2015
Liabilities			
Current liabilities			
Trade and other payables	235.5	217.6	-17.9
Bonds and borrowings	20.0	20.0	-0.0
Other financial liabilities	7.6	1.0	-6.6
Income taxes payable	7.8	6.9	-0.9
Provisions	19.4	21.1	1.7
Other current liabilities	6.7	4.5	-2.3
Subtotal	297.1	271.1	-26.0
Liabilities directly associated with assets held for sale	0.4	-	-0.4
Total current liabilities	297.5	271.1	-26.4
Non-current liabilities			
Bonds and borrowings	201.0	201.0	0.0
Other financial liabilities	8.3	8.4	0.1
Post employment benefit liabilities	11.6	11.9	0.2
Provisions	2.7	2.6	-0.1
Deferred tax liabilities	88.4	74.0	-14.4
Other non-current liabilities	65.7	61.7	-4.0
Total non-current liabilities	377.7	359.6	-18.2
Total liabilities	675.2	630.6	-44.6
Equity			
Equity attributable to owners of the Company			
Share capital	50.0	50.0	0.0
Capital surplus	105.3	103.9	-1.3
Treasury shares	-14.2	-64.2	-50.0
Other components of equity	169.0	171.5	2.5
Retained earnings	994.0	1,006.2	12.2
Total equity attributable to owners of the Company	1,304.1	1,267.5	-36.6
Non-controlling interests			
Non-controlling interests	3.0	2.8	-0.2
Total equity	1,307.0	1,270.2	-36.8
Total liabilities and equity	1,982.3	1,900.9	-81.4

Acquisition -50.0 (21 million shares)

Profit for the period +70.7,
Dividends -21.1,
Transfer from comprehensive income -30.8

5. Consolidated Statement of Cash Flows

(JPY Bn)

	FY2014 Q2 YTD	FY2015 Q2 YTD	YoY
Cash flows from operating activities			
Profit before tax from continuing operations	62.2	90.8	28.6
Depreciation and amortization	20.4	21.8	1.5
(Increase) decrease in receivables and payables	-16.4	-16.6	-0.2
Other, net	-16.7	-14.9	1.8
Income taxes paid	-4.2	-20.3	-16.0
Cash flows from operating activities of discontinued operations	11.5	-	-11.5
Net cash flows from operating activities	56.8	60.9	4.1
Cash flows from investing activities			
Net (increase) decrease in time deposits and securities	67.3	-281.6	-349.0
(Acquisition of) proceeds from sales of fixed assets	-38.4	-41.1	-2.7
Proceeds from sale of subsidiary	-	7.0	7.0
Net (increase) decrease in investment securities	-0.9	374.2	375.1
Other, net	-0.1	0.0	0.1
Cash flows from investing activities of discontinued operations	-2.1	-	2.1
Net cash flows from investing activities	25.8	58.5	32.7
Cash flows from financing activities			
Net (increase) decrease in borrowings	-10.0	-0.0	10.0
Repayments of bonds	-60.0	-	60.0
Purchase of treasury shares	-0.0	-50.2	-50.2
Dividends paid	-21.1	-21.1	0.0
Other, net	-0.5	-0.7	-0.2
Cash flows from financing activities of discontinued operations	-0.3	-	0.3
Net cash flows from financing activities	-92.0	-72.0	19.9
Net increase (decrease) in cash and cash equivalents	-9.4	47.3	56.7
Cash and cash equivalents at the beginning of the period	183.1	189.4	6.3
Effect of exchange rate changes on cash and cash equivalents	6.6	-1.4	-8.0
Cash and cash equivalents at the end of the period	180.3	235.4	55.1
* Free cash flows (Cash flows from operating activities and investing activities)	82.6	119.4	36.8

Increase in time deposits and securities

Sale of Sun Pharma shares +378.5

6. Number of Employees

	Sep. 2014	Mar. 2015	Sep. 2015
	Results	Results	Results
Consolidated	17,298	16,428	16,377
Japan	9,201	8,543	8,598
North America	3,502	3,322	3,295
Europe	2,116	2,094	2,063
Others	2,479	2,469	2,421

7. Capital Expenditure and Depreciation and Amortization

	(JPY Bn)	FY2014 Q2 YTD Results	FY2014 Results	FY2015 Q2 YTD Results	FY2015 Forecast
Capital expenditure		15.0	36.3	14.2	30.3
Depreciation and amortization		20.4	42.0	21.8	41.9
Property, plant and equipment		13.1	27.0	13.8	-
Intangible assets		7.3	15.1	8.1	-

8. Summary of Product Outlines

Brand Name	Generic Name	Therapeutic Category	Launched	Origin	Marketing Alliance	Type of Alliance
Japan						
Olmetec	olmesartan	antihypertensive	2004	Daiichi Sankyo		
Nexium	esomeprazole	proton pump inhibitor	2011	AstraZeneca	AstraZeneca	Co-promotion (DS: Sales)
Memary	memantine	treatment for Alzheimer's disease	2011	Merz		
Loxonin			1986	Daiichi Sankyo		
Loxonin Poultice	loxoprofen	analgesic and anti-inflammatory	2006	Lead Chemical		
Loxonin Tape			2008	Lead Chemical		
Loxonin Gel			2010	Daiichi Sankyo		
Cravit			levofloxacin	antibacterial	1993	Daiichi Sankyo
Rezaltas	olmesartan / azelnidipine	antihypertensive	2010	Daiichi Sankyo		
Artist	carvedilol	antihypertensive	1993	Roche		
Omnipaque	iohexol	contrast medium	1987	GE Healthcare		
Mevalotin	pravastatin	antihyperlipidemic	1989	Daiichi Sankyo		
Ranmark	denosumab	anti-RANKL antibody	2012	Amgen		
Inavir	laninamivir	anti-influenza	2010	Daiichi Sankyo		
Urief	silodosin	treatment for dysuria	2006	Kissei	Kissei	Co-marketing
Pralia	denosumab	anti-RANKL antibody	2013	Amgen		
Lixiana	edoxaban	anticoagulant Direct Oral Factor Xa Inhibitor	2011	Daiichi Sankyo		
Efient	prasugrel	antiplatelet	2014	Daiichi Sankyo Ube Industries		
Tenelia	teneligliptin	type 2 diabetes	2012	Mitsubishi Tanabe	Mitsubishi Tanabe	Co-marketing
Daiichi Sankyo, Inc. (US)						
Olmesartan						
Benicar	olmesartan		2002			
Benicar HCT	olmesartan / hydrochlorothiazide	antihypertensive	2003	Daiichi Sankyo		
Azor	olmesartan / amlodipine		2007			
Tribenzor	olmesartan / amlodipine / hydrochlorothiazide		2010			
Welchol	colesevelam		antihyperlipidemic / type 2 diabetes		2000	Genzyme
Effient	prasugrel	antiplatelet	2009	Daiichi Sankyo Ube Industries	Lilly	Co-promotion (DS: Co-pro revenue)
Savaysa	edoxaban	anticoagulant Direct Oral Factor Xa Inhibitor	2015	Daiichi Sankyo		
Movantik	naloxegol	opioid-induced constipation	2015	Nektar AstraZeneca	AstraZeneca	Co-promotion (DS: Co-pro revenue)
Luitpold Pharmaceuticals, Inc. (US)						
Venofer	iron sucrose injection	iron deficiency anemia	2000	Vifor Pharma	Fresenius	Co-marketing
Injectafer	ferric carboxymaltose injection	iron deficiency anemia	2013	Vifor Pharma		
Daiichi Sankyo Europe GmbH						
Olmesartan						
Olmetec	olmesartan		2002			
Olmetec Plus	olmesartan / hydrochlorothiazide	antihypertensive	2005	Daiichi Sankyo	Menarini Pfizer Nycomed	Co-marketing
Sevikar	olmesartan / amlodipine		2009			
Sevikar HCT	olmesartan / amlodipine / hydrochlorothiazide		2010			
Efient	prasugrel		antiplatelet			
Lixiana	edoxaban	anticoagulant Direct Oral Factor Xa Inhibitor	2015	Daiichi Sankyo		

<9. Quarterly Data>

1. Consolidated Statement of Profit or Loss

JPY Bn	FY2014	FY2014	FY2014	FY2014	FY2014				FY2015	FY2015	FY2015	FY2015	FY2015	
	Q1	Q2	Q3	Q4	to revenue	Results	YoY	YoY (%)	Q1	Q2	Q3	Q4	to revenue	Results
	Results	Results	Results	Results					Results	Results	Results	Results		
Revenue	213.7	215.9	264.8	225.0	100.0%	919.4	20.2	+2.3%	238.4	240.4			100.0%	478.8
Cost of sales	64.6	66.2	90.1	102.2	35.1%	323.1	40.2	+14.2%	74.0	75.0			31.1%	148.9
(excl. Special items)	64.6	66.2	87.9	67.2	31.1%	285.9	7.1	+2.6%	76.3	76.1			31.8%	152.4
(Special items)	-	-	2.2	35.0	4.0%	37.2	33.1	+813.2%	-2.4	-1.1			-0.7%	-3.5
Gross Profit	149.1	149.7	174.7	122.8	64.9%	596.3	-20.0	-3.2%	164.5	165.4			68.9%	329.8
SG&A expenses	74.9	78.7	84.1	93.4	36.0%	331.2	8.5	+2.6%	71.6	72.8			30.2%	144.5
(excl. Special items)	74.9	74.7	79.4	89.6	34.7%	318.6	-4.1	-1.3%	75.6	77.1			31.9%	152.7
(Special items)	-	4.0	4.7	3.8	1.4%	12.6	12.6	-53017.5%	-3.9	-4.3			-1.7%	-8.2
R&D expenses	41.4	43.5	50.8	55.0	20.7%	190.7	10.0	+5.5%	43.7	44.7			18.5%	88.4
(excl. Special items)	41.4	43.5	46.4	54.9	20.3%	186.2	5.6	+3.1%	43.7	44.7			18.5%	88.4
(Special items)	-	-	4.4	0.0	0.5%	4.4	4.4	-	-	-			-	-
Operating Profit	32.8	27.4	39.7	-25.6	8.1%	74.4	-38.5	-34.1%	49.1	47.9			20.3%	97.0
(Operating Profit before Special items)	32.8	31.5	51.1	13.3	14.0%	128.6	11.6	+9.9%	42.9	42.5			17.8%	85.3
Financial income/expenses	0.2	2.5	5.5	-1.8		6.4	5.8		-3.7	-2.1				-5.9
Share of profit or loss of investments accounted for using the equity method	-0.3	-0.5	0.1	-0.2		-0.9	-0.3		-0.2	-0.1				-0.3
Profit before tax	32.7	29.5	45.3	-27.5	8.7%	79.9	-33.0	-29.2%	45.2	45.6			19.0%	90.8
Income taxes	11.8	15.1	14.0	-4.6		36.4	-10.8	-22.9%	11.1	10.3				21.4
Profit for the year	20.9	14.3	31.3	-22.9	4.7%	43.6	-22.2	-33.8%	34.1	35.3			14.5%	69.4
Profit attributable to owners of the Company	21.6	15.1	32.3	-22.5	5.1%	46.5	-22.3	-32.5%	34.9	35.8			14.8%	70.7
Tax rate	36.1%	51.3%	31.0%	16.7%		45.5%			24.6%	22.5%				23.5%
Overseas sales ratio	45.2%	41.1%	39.7%	45.3%		42.7%			46.8%	46.2%				46.5%
<u>Currency Rate (Average)</u>														
USD/JPY	102.16	103.05	106.88	109.94		109.94			121.37	121.80				121.80
EUR/JPY	140.06	138.91	140.31	138.78		138.78			134.16	135.07				135.07

<9. Quarterly Data>

2. Revenue of Global Products

JPY Bn	FY2014 Q1	FY2014 Q2	FY2014 Q3	FY2014 Q4	FY2014			FY2015 Q1	FY2015 Q2	FY2015 Q3	FY2015 Q4	FY2015
	Results	Results	Results	Results	Results	YoY	YoY (%)	Results	Results	Results	Results	Results
Olmesartan	75.8	66.5	77.6	73.7	293.5	-6.6	-2.2%	75.6	71.9			147.5
Olmetec (JPN)	18.7	19.1	20.6	17.9	76.3	-2.8	-3.5%	18.5	17.7			36.2
Rezaltas (JPN)	4.5	4.5	5.0	4.3	18.4	-0.0	-0.3%	4.6	4.3			8.9
Benicar/Benicar HCT (US)	18.9	15.1	21.0	22.0	77.0	-8.9	-10.3%	19.8	20.5			40.3
Azor (US)	4.1	3.9	5.4	4.9	18.3	0.9	+4.9%	5.8	4.6			10.4
Tribenzor (US)	2.7	2.5	3.3	2.8	11.3	2.3	+25.3%	3.1	3.2			6.3
Olmetec/Olmetec Plus (EU)	11.1	9.3	8.6	8.7	37.8	-6.8	-15.2%	8.9	8.2			17.1
Sevikar (EU)	5.3	4.2	3.9	4.1	17.6	4.1	+30.2%	4.5	4.1			8.5
Sevikar HCT (EU)	3.3	2.1	2.2	2.2	9.9	2.3	+29.9%	2.5	2.2			4.6
Other subsidiaries, export, etc	7.1	5.8	7.4	6.7	27.0	2.3	+9.4%	7.9	7.1			15.0
Prasugrel	5.8	5.9	6.7	6.6	24.9	2.6	+11.7%	7.8	7.4			15.3
Effient alliance revenue (US)	4.2	4.2	4.6	4.5	17.6	2.1	+13.7%	5.2	5.4			10.6
Effient alliance revenue and others (EU)	1.2	1.2	1.3	1.1	4.8	0.1	+1.7%	1.1	1.1			2.2
Effient (JPN)	0.2	0.1	0.2	0.2	0.7	0.7	-	1.2	0.6			1.8
Other subsidiaries, export, etc	0.2	0.4	0.5	0.8	1.9	-0.3	-12.2%	0.3	0.4			0.7
Edoxaban	0.1	0.1	1.9	2.1	4.3	3.9	+967.0%	1.8	3.5			5.3
Lixiana (JPN)	0.1	0.1	1.9	1.4	3.6	3.2	+792.8%	2.1	3.2			5.4
Savaysa (US)				0.7	0.7	0.7	-	-0.3	0.1			-0.2
Lixiana (EU)					-	-	-	0.0	0.1			0.2

3. Revenue by Business Units and Products (1)	FY2014 Q1	FY2014 Q2	FY2014 Q3	FY2014 Q4	FY2014			FY2015 Q1	FY2015 Q2	FY2015 Q3	FY2015 Q4	FY2015
	Results	Results	Results	Results	Results	YoY	YoY (%)	Results	Results	Results	Results	Results
JPY Bn												
Japan	108.0	114.6	145.2	112.7	480.5	-5.5	-1.1%	114.2	113.6			227.8
Olmotec	18.7	19.1	20.6	17.9	76.3	-2.8	-3.5%	18.5	17.7			36.2
Nexium	15.3	16.8	23.7	13.6	69.3	15.1	+27.9%	19.1	19.6			38.7
Memary	7.9	8.9	10.8	9.3	36.8	3.5	+10.5%	10.2	10.2			20.5
Loxonin	12.2	13.2	13.3	10.9	49.5	-9.8	-16.5%	12.6	11.8			24.4
Cravit	6.9	7.3	8.8	4.9	27.8	-5.7	-16.9%	4.6	4.4			9.0
Rezaltas	4.5	4.5	5.0	4.3	18.4	-0.0	-0.3%	4.6	4.3			8.9
Artist	4.8	4.7	4.7	4.0	18.1	-4.3	-19.1%	4.1	3.8			7.9
Omnipaque	4.2	4.4	4.7	3.9	17.2	-2.5	-12.5%	4.2	4.2			8.5
Mevalotin	4.2	4.1	4.3	3.6	16.2	-5.3	-24.8%	3.6	3.4			7.0
Ranmark	2.1	2.6	2.9	2.6	10.2	2.1	+26.1%	2.9	3.0			5.9
Inavir	0.3	0.0	7.9	8.4	16.6	3.1	+23.4%	0.0	0.0			0.0
Urief	2.7	2.9	3.1	2.8	11.5	0.1	+0.7%	2.9	2.8			5.7
Pralia	1.3	1.7	2.1	2.2	7.3	4.2	+131.8%	2.6	2.8			5.4
Lixiana	0.1	0.1	1.9	1.4	3.6	3.2	+792.8%	2.1	3.2			5.4
Efient	0.2	0.1	0.2	0.2	0.7	0.7	-	1.2	0.6			1.8
Teneria	1.5	1.8	2.2	2.1	7.6	6.0	+390.5%	2.4	3.0			5.3
Daiichi Sankyo Espha products	3.5	3.3	4.8	3.3	14.9	2.4	+19.4%	4.3	4.3			8.6
Vaccines business	5.8	6.7	13.1	6.6	32.2	-5.3	-14.1%	6.4	8.0			14.4
Daiichi Sankyo Healthcare (OTC)	9.4	13.3	14.3	10.8	47.8	-0.3	-0.5%	10.8	13.8			24.6

3. Revenue by Business Units and Products (2)

JPY Bn	FY2014 Q1	FY2014 Q2	FY2014 Q3	FY2014 Q4	FY2014			FY2015 Q1	FY2015 Q2	FY2015 Q3	FY2015 Q4	FY2015
	Results	Results	Results	Results	Results	YoY	YoY (%)	Results	Results	Results	Results	Results
Daiichi Sankyo, Inc. (US)	41.6	36.5	48.1	46.8	173.0	1.2	+0.7%	48.0	45.4			93.4
Olmesartan	25.7	21.5	29.7	29.6	106.6	-5.7	-5.1%	28.8	28.3			57.1
Benicar/Benicar HCT	18.9	15.1	21.0	22.0	77.0	-8.9	-10.3%	19.8	20.5			40.3
Azor	4.1	3.9	5.4	4.9	18.3	0.9	+4.9%	5.8	4.6			10.4
Tribenzor	2.7	2.5	3.3	2.8	11.3	2.3	+25.3%	3.1	3.2			6.3
Welchol	11.3	10.5	13.4	12.3	47.4	5.1	+12.1%	13.5	10.6			24.2
Effient	4.2	4.2	4.6	4.5	17.6	2.1	+13.7%	5.2	5.4			10.6
Savaysa				0.7	0.7	0.7	-	-0.3	0.1			-0.2
Movantik					-	-	-	0.2	0.4			0.6
Luitpold Pharmaceuticals, Inc. (US)	12.5	14.3	16.2	14.4	57.4	17.8	+44.8%	21.5	24.9			46.4
Venofer	7.2	7.0	8.6	5.8	28.6	3.7	+14.9%	9.1	6.9			16.0
Injectafer	1.5	1.5	2.2	2.6	7.6	6.3	+483.4%	3.9	4.0			7.9
Daiichi Sankyo Europe GmbH	24.5	20.0	20.1	18.9	83.5	-0.4	-0.5%	20.2	19.0			39.2
Olmesartan	19.7	15.7	14.8	15.0	65.2	-0.4	-0.6%	15.8	14.4			30.2
Olmetec/Olmetec Plus	11.1	9.3	8.6	8.7	37.8	-6.8	-15.2%	8.9	8.2			17.1
Sevikar	5.3	4.2	3.9	4.1	17.6	4.1	+30.2%	4.5	4.1			8.5
Sevikar HCT	3.3	2.1	2.2	2.2	9.9	2.3	+29.9%	2.5	2.2			4.6
Efient	1.2	1.2	1.3	1.1	4.8	0.1	+1.7%	1.1	1.1			2.2
Lixiana					-	-	-	0.0	0.1			0.2
Asia, South and Central America (ASCA)	15.1	14.8	18.9	18.6	67.5	8.8	+14.9%	21.4	21.3			42.7
Daiichi Sankyo China	5.4	6.1	7.3	8.5	27.4	6.1	+28.8%	7.9	8.6			16.4
Daiichi Sankyo Taiwan	1.2	1.1	1.2	1.3	4.9	0.4	+8.8%	1.4	1.3			2.7
Daiichi Sankyo Korea	2.7	1.7	2.0	2.5	8.9	-0.2	-2.0%	2.4	2.4			4.8
Daiichi Sankyo Thailand	0.7	0.9	1.0	1.0	3.7	1.2	+47.1%	0.8	1.0			1.8
Daiichi Sankyo Brasil Farmacêutica	2.3	2.0	2.6	1.5	8.4	0.9	+12.0%	2.6	1.9			4.5
Daiichi Sankyo Venezuela	1.2	1.8	2.9	2.1	8.1	1.2	+17.6%	3.1	2.4			5.5

3. Revenue by Business Units and Products (3)

[Reference] Revenue in Local Currency

	FY2014 Q1	FY2014 Q2	FY2014 Q3	FY2014 Q4	FY2014			FY2015 Q1	FY2015 Q2	FY2015 Q3	FY2015 Q4	FY2015
	Results	Results	Results	Results	Results	YoY	YoY (%)	Results	Results	Results	Results	Results
USD Mn												
Daiichi Sankyo, Inc. (US)	407	351	423	393	1,574	-140	-8.2%	396	371			766
Olmesartan	251	207	262	249	969	-151	-13.5%	237	232			469
Benicar/Benicar HCT	185	145	185	186	700	-156	-18.2%	163	168			331
Azor	40	38	48	41	166	-8	-4.4%	48	38			86
Tribenzor	26	24	30	23	103	13	+14.3%	26	26			52
Welchol	111	101	117	102	431	9	+2.2%	112	87			199
Effient	42	41	40	37	160	6	+3.7%	43	44			87
Savaysa				6	6	6	-	-2	1			-1
Movantik					-	-	-	1	3			5
USD Mn												
Luitpold Pharmaceuticals, Inc. (US)	122	137	142	120	522	127	+32.1%	177	204			381
Venofer	70	68	75	47	260	12	+4.7%	75	57			132
Injectafer	14	14	19	22	69	56	+431.9%	32	33			65
EUR Mn												
Daiichi Sankyo Europe GmbH	175	146	140	141	602	-23	-3.6%	151	140			290
Olmesartan	141	114	103	112	470	-19	-3.8%	118	106			224
Olmetec/Olmetec Plus	79	68	60	65	272	-59	-17.9%	66	60			126
Sevikar	38	31	27	30	127	26	+26.1%	33	30			63
Sevikar HCT	24	15	15	17	71	15	+25.8%	18	16			34
Efient	8	8	9	8	34	-1	-1.6%	8	8			16
Lixiana					-	-	-	0	1			1

<10. Historical Data>

1. Revenue of Global Products

	FY2010	FY2011	FY2012	FY2013	FY2014
JPY Bn	Results	Results	Results	Results	Results
Olmesartan	241.5	249.7	258.9	300.2	293.5
Olmetec (JPN)	82.3	80.9	78.3	79.1	76.3
Rezaltas (JPN)	4.7	13.5	16.9	18.5	18.4
Benicar/Benicar HCT (US)	79.7	71.3	73.2	85.9	77.0
Azor (US)	13.3	12.0	14.8	17.4	18.3
Tribenzor (US)	1.5	4.6	6.8	9.0	11.3
Olmetec/Olmetec Plus (EU)	36.7	36.6	32.6	44.5	37.8
Sevikar (EU)	8.4	11.0	10.8	13.5	17.6
Sevikar HCT (EU)	1.1	3.4	4.7	7.6	9.9
Other subsidiaries, export, etc	13.9	16.5	20.7	24.7	27.0
Prasugrel	5.2	10.9	14.4	22.3	24.9
Effient alliance revenue (US)	3.4	7.9	10.5	15.4	17.6
Effient alliance revenue and others (EU)	1.8	2.9	3.9	4.7	4.8
Effient (JPN)					0.7
Other subsidiaries, export, etc				2.2	1.9
Edoxaban				0.4	4.3
Lixiana (JPN)				0.4	3.6
Savaysa (US)					0.7
Lixiana (EU)					

2. Revenue by Business Units and Products (1)

	FY2010	FY2011	FY2012	FY2013	FY2014
JPY Bn	Results	Results	Results	Results	Results
Japan	416.0	409.8	442.5	486.0	480.5
Olmetec	82.3	80.9	78.3	79.1	76.3
Nexium		3.9	21.6	54.2	69.3
Memary		9.8	23.8	33.3	36.8
Loxonin	54.2	61.0	59.6	59.3	49.5
Cravit	32.4	36.3	35.9	33.5	27.8
Rezaltas	4.7	13.5	16.9	18.5	18.4
Artist	23.7	24.5	22.4	22.4	18.1
Omnipaque	25.0	23.5	20.2	19.7	17.2
Mevalotin	38.1	33.1	25.8	21.5	16.2
Ranmark			4.4	8.1	10.2
Inavir	6.6	10.7	11.1	13.4	16.6
Urief	10.1	11.0	11.1	11.4	11.5
Pralia				3.2	7.3
Lixiana		0.3	0.3	0.4	3.6
Efient					0.7
Teneria			1.3	1.5	7.6
Daiichi Sankyo Espha products	4.6	9.9	11.1	12.5	14.9
Vaccines business	17.8	21.2	39.1	37.5	32.2
Daiichi Sankyo Healthcare (OTC)	44.8	45.9	47.1	48.1	47.8

2. Revenue by Business Units and Products (2)

	FY2010	FY2011	FY2012	FY2013	FY2014
JPY Bn	Results	Results	Results	Results	Results
Daiichi Sankyo, Inc. (US)	130.5	127.1	142.3	171.8	173.0
Olmesartan	94.5	87.9	94.9	112.3	106.6
Benicar/Benicar HCT	79.7	71.3	73.2	85.9	77.0
Azor	13.3	12.0	14.8	17.4	18.3
Tribenzor	1.5	4.6	6.8	9.0	11.3
Welchol	28.5	26.9	33.1	42.3	47.4
Effient	3.4	7.9	10.5	15.4	17.6
Savaysa					0.7
Movantik					
Luitpold Pharmaceuticals, Inc. (US)	53.9	44.7	38.6	39.6	57.4
Venofer	30.7	24.8	23.6	24.9	28.6
Injectafer				1.3	7.6
Daiichi Sankyo Europe GmbH	66.4	70.2	64.4	83.9	83.5
Olmesartan	46.2	51.0	48.0	65.6	65.2
Olmetec/Olmetec Plus	36.7	36.6	32.6	44.5	37.8
Sevikar	8.4	11.0	10.8	13.5	17.6
Sevikar HCT	1.1	3.4	4.7	7.6	9.9
Efient		2.9	3.9	4.7	4.8
Lixiana					
Asia, South and Central America (ASCA)	27.4	28.6	45.4	58.8	67.5
Daiichi Sankyo China	10.8	9.7	16.4	21.2	27.4
Daiichi Sankyo Taiwan	3.4	3.1	3.3	4.5	4.9
Daiichi Sankyo Korea	4.0	4.6	5.3	9.1	8.9
Daiichi Sankyo Thailand	1.2	1.2	1.4	2.5	3.7
Daiichi Sankyo Brasil Farmacêutica	5.2	5.5	6.6	7.5	8.4
Daiichi Sankyo Venezuela	2.9	4.2	6.7	6.9	8.1

2. Revenue by Business Units and Products (3)**[Reference] Revenue in Local Currency**

	FY2010	FY2011	FY2012	FY2013	FY2014
	Results	Results	Results	Results	Results
USD Mn					
Daiichi Sankyo, Inc. (US)	1,522	1,608	1,713	1,714	1,574
Olmesartan	1,102	1,112	1,142	1,120	969
Benicar/Benicar HCT	930	901	881	857	700
Azor	155	152	179	174	166
Tribenzor	17	58	82	90	103
Welchol	333	340	399	422	431
Effient	40	100	127	154	160
Savaysa					6
Movantik					
USD Mn					
Luitpold Pharmaceuticals, Inc. (US)	629	566	465	395	522
Venofer	358	314	284	248	260
Injectafer				13	69
EUR Mn					
Daiichi Sankyo Europe GmbH	587	644	601	624	602
Olmesartan	408	468	448	488	470
Olmetec/Olmetec Plus	324	336	304	331	272
Sevikar	74	101	100	100	127
Sevikar HCT	10	31	44	57	71
Efient		27	36	35	34
Lixiana					

◆ Launched/Approved

Generic Name	Class	Indication	Region	Status	Remarks
Edoxaban	Factor Xa inhibitor	Atrial fibrillation (AF)	EU	Approved Launched	Launched in UK (15/7*) and obtained recommendation by National Institute for Health and Care Excellence (NICE) (15/9), Launched in Germany (15/8) * means Jul, 2015, ditto
		Venous thromboembolism (VTE)	S. Korea	Approved Launched	Approved in Aug 2015
<Summary> The once daily oral anti coagulant (FXa inhibitor) discovered by Daiichi Sankyo. Edoxaban specifically, reversibly and directly inhibits the enzyme, Factor Xa, a clotting factor in the blood. Launched in Japan in July 2011 as the prevention of venous thromboembolism (VTE) in patients with total knee arthroplasty, total hip arthroplasty and hip fracture surgery. Additional indications for AF/VTE was approved in September 2014 and 60 mg tablet was launched in December 2014. Launched in US, Switzerland, UK and Germany in February, May, July and August 2015, respectively. Approved in South Korea in August 2015.					
Levofloxacin	New quinolone	Infection disease	JP	Approved Launched	Additional indication: Injection: urology, surgery, and gynecology (15/9) Tablets&Granules: tuberculosis (15/8)
<Summary> Levofloxacin injection formulation, which was launched in 2011 for the treatment in respiratory tract infection. As LCM programme, the trials for urinary tract infection, surgical infection and gynecological infection are completed.					
Carvedilol	β adrenergic receptor blocker	Tachycardiac atrial fibrillation	JP	Approved Launched	Additional indication. Approved in Aug 2015
<Summary> Non-selective beta blocker with alpha-1 blockade property. Carvedilol was launched for indications of essential hypertension, renal parenchymal hypertension, and angina in May 1993. Indication of chronic heart failure was approved in October, 2002. Regarding atrial fibrillation indication, the clinical trial was conducted to respond to a request from academic societies, and the approval was obtained in August 2015.					
[Brand Name: Squarekids] Precipitated and purified pertussis-diphtheria-tetanus-inactivated polio vaccine	DPT-IPV vaccine	Prevention of pertussis, diphtheria, tetanus and poliomyelitis	JP	Approved	Approved in July 2014 (KDSV)
<Summary> This vaccine is a product made of precipitated and purified pertussis, diphtheria, tetanus (DPT vaccine) of Kitasato Daiichi Sankyo and inactivated polio vaccine (Salk vaccine) of Sanofi Pasteur in a pre-filled syringe, and is the first 4-valent combination vaccine in Japan that contains inactivated polio vaccine (Salk vaccine).					

Underline: change after FY2015 Q1 Financial Announcement in Jul 2015

◆ Filed

Product Code Number/Generic Name	Class	Target indication	Region	Filing year/month
Edoxaban	Factor Xa inhibitor	Atrial fibrillation (AF)	ASCA etc	BR (14/6), TW (14/7), TH(15/7) AU(15/8), HK(15/8), CN(15/8), CA(15/8)
		Venous thromboembolism (VTE)	ASCA etc	BR (14/6), TW (14/7), TH(15/7) AU(15/8), HK(15/8), CN(15/8), CA(15/8)
<Summary> The once daily oral anti coagulant (FXa inhibitor) discovered by Daiichi Sankyo. Edoxaban specifically, reversibly and directly inhibits the enzyme, Factor Xa, a clotting factor in the blood.				
VN-100	Intradermal influenza HA vaccine	Prevention of seasonal Influenza	JP	Submitted by Japan Vaccine in April 2015
<Summary> The Vaccine is a pre-filled syringe type, intradermal influenza HA vaccine co-developed by four companies [Daiichi Sankyo, Terumo, Japan Vaccine and Kitasato Daiichi Sankyo Vaccine Co., Ltd.]. The intradermal injection device for this vaccine is developed by Terumo. This device, which offers a more easy-to-use, surefire method to administer the vaccine than current methods. The device is also expected to ease patient hesitation to be injected and lower the risk of damaging peripheral blood vessels and nerves within the subcutaneous tissue.				
VN-101	Cell-culture H5N1 flu vaccine	Prevention of H5N1 influenza	JP	Submitted in August 2015 for pediatric use with optimal dose
<Summary> This vaccine is a cell-culture H5N1 flu vaccine that has developed by Daiichi Sankyo and Kitasato Daiichi Sankyo Vaccine(KDSV). KDSV was submitted a supplemental application for optimization of pediatric use.				

Underline: change after FY2015 Q1 Financial Announcement in Jul 2015

◆ Under development (Phase1-3)

Generic Name / Project Code Number	Class	Target indication	Stage	target FY for approval/launch basically for P3	Remarks
Prasugrel	Anti-platelet agent	Ischemic stroke	JP P3	2017	additional indication
		Sickle cell disease	US P3	2016	additional indication
Denosumab	Anti-RANKL antibody	Breast cancer adjuvant	JP P3	2017 →2020	additional indication
		Rheumatoid arthritis	JP P3	2017	additional indication
Tivantinib	MET inhibitor	Hepatocellular cancer	US/EU P3	2018	
Nimotuzumab	Anti-EGFR antibody	Gastric cancer	JP P3	2019 -	
		Esophageal cancer	JP P1	-	
Vemurafenib	BRAF inhibitor	Melanoma adjuvant	US/EU P3	-	additional indication. Licensee Roche is conducting the study. Submission in 2016 is planned.
Quizartinib	FLT3-ITD inhibitor	Acute myeloid leukemia	US/EU P3	2018	Relapsed and refractory AML patients
Pexidartinib/PLX3397	FMS/KIT/FLT3-ITD inhibitor	Tenosynovial Giant Cell Tumor (TGCT)	US/EU P3	2019	including pigmented villonodular synovitis
		Glioblastoma	US P2	-	
		Melanoma	US P2	-	
		Melanoma, solid tumor	US P1/2	-	combination with pembrolizumab in collaboration with Merck
Mirogabalin	α2δ ligand	Fibromyalgia	US/EU P3	2019	
		Diabetic peripheral neuropathic pain	JP/Asia P3	2018	
		Postherpetic neuralgia	JP/Asia P3	2018	
Hydromorphone	Opioid mu-receptor agonist	Cancer pain	JP P3	2017	
CHS-0214	TNFα inhibitor	Rheumatoid Arthritis	JP P3	2017	etanercept biosimilar
CL-108	Opioid mu-receptor agonist combination	Acute pain	US P3	2016	co-develop with Charleston Laboratories
<u>VN-0107/MEDI3250</u>	<u>Live attenuated influenza vaccine</u>	<u>Prevention of seasonal influenza</u>	<u>JP P3</u>	<u>2017</u>	<u>In-licensed from AZ/MedImmune. US tradename is FluMist Quadrivalent.</u>
VN-0105	DPT-IPV/Hib vaccine	Prevention of pertussis, diphtheria, tetanus, poliomyelitis and Hib	JP P3	-	co-develop with Sanofi K.K.and KDSV
CS-3150	MR antagonist	Hypertension	JP P2b	-	
		Diabetic nephropathy	JP P2b	-	
DS-8500	GPR119 agonist	Diabetes	JP P2	-	
Patritumab	Anti-HER3 antibody	Non small cell lung cancer	US/EU P2	-	
		Non small cell lung cancer	JP P1	-	
		Breast cancer	US P2	-	
		Breast cancer	JP P1	-	
		Head & Neck cancer	EU P1	-	
SUN13837	Modulator of bFGF signaling system	Spinal cord injury	US/EU P2	-	
Laninamivir	Neuraminidase inhibitor	Influenza	US/EU P2	-	out-licensing with Biota
			JP P1	-	nebulizer formulation
DS-1040	TAF1a inhibitor	Acute ischemic stroke	- P1	-	
DS-8312	Hypertriglyceridemia treatment	Hypertriglyceridemia	- P1	-	
<u>DS-2330</u>	<u>Hyperphosphatemia treatment</u>	<u>Hyperphosphatemia in chronic kidney disease (CKD)</u>	- P1	-	
<u>DS-9231/TS23</u>	<u>α2 plasmin inhibitor-inactivating antibody</u>	<u>Thrombosis (cardiovascular diseases, ischemic stroke)</u>	- P1	-	<u>In-licensed from Translational Sciences Inc.</u>
U3-1565	Anti-HB-EGF antibody	Solid cancer	US/JP P1	-	

Underline: change after FY2015 Q1 Financial Announcement in Jul 2015

◆ Under development (Phase1-3)

Generic Name / Project code number	Class	Target indication	Stage	Remarks
DS-3032	MDM2 inhibitor	Solid cancer, lymphoma	US/JP P1	-
		Leukemia	US P1	-
PLX7486	FMS/TRK inhibitor	Solid cancer	US P1	-
DS-8895	Anti-EPHA2 antibody	Solid cancer	JP P1	-
DS-8273	Anti-DR5 antibody	Solid cancer	US P1	-
PLX8394	BRAF inhibitor	Solid cancer, leukemia	US P1	-
DS-6051	NTRK/ROS1 inhibitor	Solid cancer	US P1	-
DS-5573	Anti-B7-H3 antibody	Solid cancer	JP P1	-
PLX9486	KIT inhibitor	Solid cancer	US P1	-
<u>DS-8201</u>	<u>Anti-HER2 antibody drug conjugate</u>	<u>Solid cancer</u>	<u>JP P1</u>	-
DS-1093	HIF-PH inhibitor	Anemia of chronic kidney disease	- P1	-
DS-3801	GPR 38 agonist	Chronic obstipation	- P1	-
DS-1971	Analgesic agent	Chronic pain	- P1	-
DS-1501	Anti-Siglec-15 antibody	Osteoporosis	- P1	-
<u>DS-7080</u>	<u>Angiogenesis inhibitor</u>	<u>Neovascular age-related macular degeneration (AMD)</u>	<u>P1</u>	-
<u>VN-0102/JVC-001</u>	<u>Measles-Mumps-Rubella vaccine</u>	<u>Prevention of Measles, Mumps and Rubella</u>	<u>JP P1/2</u>	<u>Japan vaccine company is conducting the phase 1/2 study</u>

Underline: change after FY2015 Q1 Financial Announcement in Jul 2015

◆ Stage-up (major changes from the FY2015 Q1 financial announcement in July 2015)

Generic Name / Project code number	Class	Target indication	Current stage	Remarks
Edoxaban	FXa inhibitor	Atrial Fibrillation (AF) Venous thromboembolism (VTE)	EU Launched	Recommended by NICE in Sep/Aug 2015, Launched in Germany (15/8)
			KR Approved	Approved in Aug 2015
			ASCA etc. Submitted	Submitted in AU, HK, CN and CA (15/8)
Levofloxacin	New quinolone	Infection disease	JP Approved Launched	Additional indication: Injection: urology, surgery, and gynecology (15/9) Tablets&Granules: tuberculosis (15/8)
Carvedilol	β blocker	Tachycardiac atrial fibrillation	JP Approved Launched	Additional indication Approved and launched in Aug 2015
VN-101	Cell-culture H5N1 flu vaccine	Prevention of H5N1 influenza	JP Filed	Submitted in August 2015 for pediatric use with optimal dose
VN-0107/MEDI3250	Live attenuated influenza vaccine	Prevention of seasonal influenza	JP P3	In-licensed from AZ/MedImmune. US tradename is FluMist Quadrivalent.
DS-2330	Hyperphosphatemia treatment	Hyperphosphatemia in chronic kidney disease (CKD)	- P1	
DS-9231/TS23	α 2 plasmin inhibitor-inactivating antibody	Thrombosis (cardiovascular diseases, ischemic stroke)	- P1	In-licensed from Translational Sciences Inc.
DS-8201	Anti-HER2 antibody drug conjugate	Solid cancer	JP P1	
DS-7080	Angiogenesis inhibitor	Neovascular age-related macular degeneration (AMD)	- P1	
Laninamivir	Neuraminidase inhibitor	Influenza	JP P1	Nebulizer formulation
VN-0102/JVC-001	Measles-Mumps-Rubella vaccine	Prevention of Measles, Mumps and Rubella	JP P1/2	Japan vaccine company is conducting the phase 1/2 study

◆ Discontinue (major changes from the FY2015 Q1 financial announcement in July 2015)

Generic Name / Project code number	Class	Target indication	Stage
loforminol / GE-145	X-ray contrast media	Angiography	JP P2
< Reason for discontinuation > Daiichi Sankyo decided to discontinue the development after reviewing its study results.			

◆ Major R&D Pipeline Table

As of October 2015

Therapeutic Area	Phase1	Phase2	Phase3	Application
Cardiovascular - Metabolics	<p>DS-1040 (Acute ischemic stroke / TAFIa inhibitor)</p> <p>DS-8312 (Hypertriglyceridemia)</p> <p>DS-2330 (Hyperphosphatemia)</p> <p>DS-9231/TS23 (Thrombosis (cardiovascular diseases, ischemic stroke)/α2 plasmin inhibitor-inactivating antibody)</p>	<p>CS-3150 (JP) (Hypertension / MR antagonist)</p> <p>CS-3150 (JP) (Diabetic nephropathy / MR antagonist)</p> <p>DS-8500 (JP) (Diabetes / GPR119 agonist)</p>	<p>Prasugrel (JP) (CS-747 / Ischemic stroke / anti-platelet agent)</p> <p>Prasugrel (US) (CS-747 / Sickle cell disease / anti-platelet agent)</p>	<p>Edoxaban (S. Korea) (DU-176b / AF / oral factor Xa inhibitor) →</p> <p>Edoxaban (ASCA etc.) (DU-176b / AF / oral factor Xa inhibitor)</p> <p>Edoxaban (S. Korea) (DU-176b / VTE / oral factor Xa inhibitor) →</p> <p>Edoxaban (ASCA etc.) (DU-176b / VTE / oral factor Xa inhibitor)</p>
Oncology	<p>U3-1565 (US/JP) (Anti-HB-EGF antibody)</p> <p>DS-3032 (US/JP) (MDM2 inhibitor)</p> <p>PLX7486 (US) (FMS/TRK inhibitor)</p> <p>DS-8895 (JP) (Anti-EPHA2 antibody)</p> <p>DS-8273 (US) (Anti-DR5 antibody)</p> <p>PLX8394 (US) (BRAF inhibitor)</p> <p>DS-6051 (US) (NTRK/ROS1 inhibitor)</p> <p>DS-5573 (JP) (Anti-B7-H3 antibody)</p> <p>PLX9486 (US) (KIT inhibitor)</p> <p>DS-8201 (JP) (Anti-HER2 ADC)</p>	<p>Patritumab (US/EU) (U3-1287 / Anti-HER3 antibody)</p> <p>Pexidartinib (US) (PLX3397 / FMS/KIT/FLT3-ITD inhibitor)</p>	<p>Tivantinib (US/EU) (ARQ 197 / HCC / MET inhibitor)</p> <p>Denosumab (JP) (AMG 162 / Breast cancer adjuvant / Anti-RANKL antibody)</p> <p>Nimotuzumab (JP) (DE-766 / Gastric cancer / Anti-EGFR antibody)</p> <p>Vemurafenib (US/EU) (PLX4032 / Melanoma adjuvant / BRAF inhibitor)</p> <p>Quizartinib (US/EU) (AC220 / AML / FLT3-ITD inhibitor)</p> <p>Pexidartinib (US/EU) (PLX3397 / TGCT / FMS/KIT/FLT3-ITD inhibitor)</p>	
Others	<p>DS-1093 (Anemia of chronic kidney disease/HIF-PH inhibitor)</p> <p>DS-3801 (Chronic constipation/GPR38 agonist)</p> <p>DS-1971 (Chronic pain)</p> <p>DS-1501 (Osteoporosis / Anti-Siglec-15 antibody)</p> <p>DS-7080 (AMD / Angiogenesis inhibitor)</p> <p>VN-0102/JVC-001 (JP) (Measles/Mumps/Rubella vaccine)</p>	<p>SUN13837 (US/EU) (Spinal cord injury / Modulator of bFGF signaling system)</p> <p>Laninamivir (US/EU) (CS-8958 / anti-influenza / Out licensing with Biota)</p> <p>Ioforminol (JP) (GE-145 / X-ray contrast media/Angiography)</p>	<p>Mirogabalin (US/EU) (DS-5565 / Fibromyalgia / α2δ ligand)</p> <p>Mirogabalin (JP/Asia) (DS-5565 / DPNP / α2δ ligand)</p> <p>Mirogabalin (JP/Asia) (DS-5565 / PHN / α2δ ligand)</p> <p>Denosumab (JP) (AMG 162 / Rheumatoid arthritis / Anti-RANKL antibody)</p> <p>Hydromorphone (JP) (DS-7113 / Cancer pain/ Opioid mu-receptor agonist)</p> <p>CHS-0214 (JP) (Etanercept BS / Rheumatoid arthritis / TNFa inhibitor)</p> <p>CL-108 (US) (Acute pain / Opioid mu-receptor agonist combination)</p> <p>VN-0105 (JP) (DPT-IPV/Hib vaccine)</p> <p>VN-0107/MEDI3250 (JP) (Seasonal Flu/Live attenuated influenza vaccine)</p>	<p>Levofloxacin (JP) (DR-3355 / anti-infection / New quinolone) →</p> <p>Intradermal Seasonal Influenza Vaccine (VN-100 / prefilled i.d. vaccine for seasonal flu)</p> <p>VN-101 (JP) (Cell-culture H5N1 Influenza vaccine)</p>

Underline: change after FY2015 Q1 Financial Announcement in Jul 2015

Cardiovascular-Metabolics

[Project after Phase 2]

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
Edoxaban	DU-176b	Oral	Factor Xa inhibitor	- Atrial fibrillation (AF) - Venous thromboembolism (VTE)	Daiichi Sankyo	Lixiana (JP) LIXIANA (EU) SAVAYSA (US)
<p><Summary> The once daily oral anti coagulant (FXa inhibitor). Edoxaban specifically, reversibly and directly inhibits the enzyme, Factor Xa, a clotting factor in the blood. Launched in Japan in July 2011 as the prevention of venous thromboembolism (VTE) in patients with total knee arthroplasty, total hip arthroplasty and hip fracture surgery.</p> <ul style="list-style-type: none"> • Top line results of Hokusai-VTE (VTE) P3 study was presented at ESC 2013. • Top line results of ENGAGE AF-TIMI 48 (AF) P3 study was presented at AHA 2013. • AF/VTE indication: Launched (JP: Sep 2014 (Dec 2014 for 60 mg tablet), US: Feb 2015, Switzerland: May 2015, UK: Jul 2015, Germany: Aug 2015), Approved in South Korea in Aug 2015. 						

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
Prasugrel	CS-747	Oral	Anti-platelet agent	- Ischemic stroke - Sickle cell disease	Daiichi Sankyo Ube Industries	Effient (US, Asia) Efient (JPN, EU)
<p><Summary> The oral antiplatelet agent. Prasugrel helps to keep blood platelets from clumping together and developing a blockage in an artery.</p> <ul style="list-style-type: none"> • Co-development with Eli Lilly in the US and EU, development by Daiichi Sankyo in Japan. • [JP] Approved in Mar-2014 for the ischemic heart disease undergoing PCI and launched in May-2014. P3 studies for ischemic stroke are on-going. • [US] P3 study in pediatric sickle cell disease patients is on-going. 						

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
-	CS-3150	Oral	MR antagonist	- Hypertension - Diabetic nephropathy	Exelixis	TBD
<p><Summary> The agent inhibits aldosterone binding to Mineralocorticoid Receptor(MR) which stimulate the sodium absorption into kidney. This agent is expected antihypertensive and organ-protective effect.</p> <ul style="list-style-type: none"> • P2 study in essential hypertension in Japan was completed. • P2 study in diabetes with albuminuria in Japan was completed. On January 2015, Ph.2bs of HTN and DN started. 						

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
-	DS-8500	Oral	GPR119 agonist	- Diabetes	Daiichi Sankyo	TBD
<p><Summary> The agent agonistically acts on GPR119 which is expressed in small intestine and spleen cells, stimulates insulin secretion, and lowers blood sugar concentration.</p>						

Oncology

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
Tivantinib	ARQ 197	Oral	MET inhibitor	- Hepatocellular cancer	ArQule	TBD
<p><Summary> The molecular-targeted agent to inhibit HGF(hepatocyte growth factor) receptor, Met which has multiple roles in intracellular signal transductions such as cancer cell proliferation, angiogenesis, invasion, and apoptosis induction.</p> <p>• A P3 clinical study for HCC with MET high patients was started in Jan-2013.</p>						
Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
Nimotuzumab	DE-766	Injection	Anti-EGFR antibody	- Gastric cancer - Esophageal cancer	InnoCIMAb	TBD
<p><Summary> The humanized monoclonal antibody to target Epidermal Growth Factor Receptor(EGFR). This antibody is expected to be a best in class EGFR, safety against the skin toxicity and the efficacy comparable to the other antibodies.</p> <p>• P3 in Japan for Gastric cancer started in April 2013.</p>						
Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
Quizartinib	AC220	Oral	FLT3-ITD inhibitor	- Acute myeloid leukemia	Daiichi Sankyo (Ambit)	TBD
<p><Summary> Kinase inhibitor against a receptor-type tyrosine kinase, FLT3. Therapeutic effect for patients with acute myeloid leukemia harboring FLT-ITD3 mutation is expected.</p>						
Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
Patritumab	U3-1287	Injection	Anti-HER3 antibody	- Non small cell lung cancer - Breast cancer - Head and neck cancer	Daiichi Sankyo (U3 Pharma)	TBD
<p><Summary> The fully human monoclonal antibody to target HER3, one of the Epidermal Growth Factor Receptor (EGFR) family of proteins. HER 3 is overexpressed in many tumors of epithelial origin and HER2/HER3 dimers and EGFR/HER3 dimers are more potent to induce tumor cell proliferation than homodimers of HER2 or EGFR.</p>						
Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
Vemurafenib	PLX4032	Oral	BRAF inhibitor	- Melanoma adjuvant	Daiichi Sankyo (Plexikon)	Zelboraf
<p><Summary> The molecular-targeted agent to inhibit BRAF V600E mutation. Launched since 2011 as personalized treatment for patients with unrespectable or metastatic melanoma. NDA for combination therapy with MEK inhibitor cobimetinib was submitted in US and EU by Roche. A Phase 1 study of a combination with anti PD-L1 monoclonal antibody atezolizumab is investigated by Roche. Another phase 1 study for triple combination with cobimetinib and atezolizumab is also conducted by Roche.</p>						
Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
Pexidartinib	PLX3397	Oral	FMS/KIT/FLT3-ITD inhibitor	- Tenosynovial Giant Cell Tumor - Glioblastoma - Melanoma	Daiichi Sankyo (Plexikon)	TBD
<p><Summary> The molecular-targeted agent to inhibit Fms, Kit and Flt3-ITD. This agent is expected to reduce tumor cell proliferation and expansion of metastases.</p>						

Others

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
Precipitated and purified pertussis-diphtheria-tetanus-inactivated polio vaccine (Salk vaccine) vaccine	DD-687	Injection	DPT-IPV vaccine	- Prevention of pertussis, diphtheria, tetanus and poliomyelitis	Daiichi Sankyo (KDSV) Sanofi Pasteur	Squarekids subcutaneous injection syringe
<p><Summary></p> <p>This vaccine is a product made of precipitated and purified pertussis, diphtheria, tetanus (DPT vaccine) of Kitasato Daiichi Sankyo and inactivated polio vaccine (Salk vaccine) of Sanofi Pasteur in a prefilled syringe, and is the first 4-valent combination vaccine in Japan that contains inactivated polio vaccine (Salk vaccine).</p> <ul style="list-style-type: none"> Approved in Jul 2014. 						

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
Levofloxacin	DR-3355	Injection	New quinolone	- Infection disease	Daiichi Sankyo	Cravit (JP) Levaquin (US) Tavanic (EU)
<p><Summary></p> <p>Levofloxacin injection formation, which was launched in 2011 for the treatment in respiratory tract infection. As LCM programme, the trials for urinary tract infection, surgical infection and gynecological infection are completed.</p> <ul style="list-style-type: none"> A P3 comparative study for urinary tract infection and 4 open studies completed. sNDA submitted in Nov 2014. sNDA approved in Sep 2015. 						

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
Intradermal Seasonal Influenza Vaccine	VN-100	Injection (prefilled syringe)	Sesonal flu vaccine	- Prevention of seasonal influenza	Daiichi Sankyo (KDSV) Terumo	TBD
<p><Summary></p> <p>The Vaccine is a pre-filled syringe type, intradermal influenza HA vaccine co-developed by four companies [Daiichi Sankyo, Terumo, Japan Vaccine and Kitasato Daiichi Sankyo Vaccine Co., Ltd.]. The intradermal injection device for this vaccine is developed by Terumo. This device, which offers a more easy-to-use, surefire method to administer the vaccine than current methods. The device is also expected to ease patient hesitation to be injected and lower the risk of damaging peripheral blood vessels and nerves within the subcutaneous tissue.</p> <ul style="list-style-type: none"> NDA submission in Apr 2014 by Japan Vaccine 						

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
-	VN-101	Injection	Cell culture H5N1 flu vaccine	- Prophylaxis of H5N1 influenza infection	Daiichi Sankyo (KDSV)	TBD
<p><Summary></p> <p>Optimization of cell-culture H5N1 flu vaccine approved in Mar. 2014 for pediatric use.</p> <ul style="list-style-type: none"> Ph3 study in Japan started in Jul. 2014. Submitted sNDA in Aug 2015. 						

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
Denosumab	AMG 162	Injection	Anti-RANKL antibody	- Breast cancer adjuvant - Rheumatoid arthritis	Amgen	SRE, GCTB: Ranmark(JP) Osteoporosis: Pralia(JP)
<p><Summary></p> <p>The fully human monoclonal antibody to target RANK Ligand, an essential mediator of osteoclast formation. Launched in Japan in April 2012 as treatment for bone complications stemming from multiple myeloma and bone metastases from solid tumors, in June 2013 as treatment for osteoporosis, and in May 2014 as treatment for giant cell tumor of bone.</p> <ul style="list-style-type: none"> July, 2007 In-licensed from Amgen. P3 : Breast cancer adjuvant, Rheumatoid arthritis. 						

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
-	CHS-0214	Injection	TNF α inhibitor	- Rheumatoid arthritis	Coherus	TBD
<p><Summary></p> <p>Biosimilar product for etanercept</p> <ul style="list-style-type: none"> Phase 3 study for patients with rheumatoid arthritis in Japan was started in August 2014. 						

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
-	CL-108	Oral	opioid mu-receptor regulator	- Acute pain	Charleston Laboratories	TBD
<p><Summary> Combination product of immediate-release promethazine, hydrocodone and acetaminophen. Reduction of Opioid-Induced Nausea and Vomiting is expected.</p> <p>• Under phase 3 development in collaboration with Charleston Laboratories</p>						
Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
Mirogabalin	DS-5565	Oral	$\alpha 2\delta$ ligand	- Fibromyalgia - Diabetic peripheral neuropathic pain - Postherpetic neuralgia	Daiichi Sankyo	TBD
<p><Summary> The pain therapy agent to reduce the neurotransmitter release from nerve terminals. This agent is expected to show the good balanced efficacy and safety profile.</p> <p>• Ph2 studies for diabetic peripheral neuropathic pain were completed. • Ph3 studies for diabetic peripheral neuropathic pain and postherpetic neuralgia are in execution . • Ph3 studies for fibromyalgia are in execution .</p>						
Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
Hydromorphone	DS-7113	Oral/ Injection	opioid mu-receptor regulator	- Cancer pain	-	TBD
<p><Summary> The opiate, narcotic analgesic that has been available outside of Japan for over 80 years and recommended in WHO guideline as a standard analgesia for cancer pain. It is designated as unapproved drug by "Study Group on Unapproved and Off-label Drugs of High Medical Need."</p> <p>• Ph2 and Ph3 studies for immediate-release tablet were completed, Ph3 studies for extended-release tablet, and Ph2/3 studies for injection formulation are ongoing.</p>						
Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
-	VN-0107 MEDI3250	Nasal spray	Seasonal flu vaccine	- Prevention of seasonal influenza	AZ/MedImmune	TBD
<p><Summary> The US brand name of this vaccine is FluMist Quadrivalent that is a live attenuated influenza vaccine which is administered as a nasal spray and contains four protective strains. Phase III safety and efficacy studies were conducted for FluMist Quadrivalent in Japanese children over the 2014-2015 influenza season and a regulatory submission is being prepared in Japan.</p> <p>• In preparation for NDA submission</p>						
Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
-	VN-0105	Injection	DPT-IPV/Hib vaccine	- Prevention of pertussis, diphtheria, tetanus, poliomyelitis and Hib	Daiichi Sankyo (KDSV) Sanofi Pasteur	TBD
<p><Summary> A combination vaccine reconstituting Hib with precipitated and purified pertussis-diphtheria-tetanus-inactivated polio vaccine (Salk vaccine) vaccine previously licensed and launched in Japan, as 1st in the class of pentavalent vaccine (DPT-IPV/Hib).</p> <p>• Ph3 study in Japan started in Oct 2014.</p>						
Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
-	SUN13837	Injection	Modulator of bFGF signaling system	- Spinal cord injury	Daiichi Sankyo (Asubio Pharma)	TBD
<p><Summary> By accelerating self-regeneration capabilities (nerve cell protection, nerve axon elongation) with bFGF like cell differentiation actions, the perceptual and motor-functional dysfunctions caused by cord injuries are to be improved.</p>						